enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$1.72−0.17 (-8.99%)
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
Earnings
enGene Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 8, 2027
Q1 FY2027 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.47
$0.57 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of enGene Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2027ended Jan 31, 2027 | Mar 8, 2027Expected | – | – | – | – |
| Q4 FY2026ended Oct 31, 2026 | Nov 12, 2026before the open | – | – | – | Release |
| Q3 FY2026ended Jul 31, 2026 | Sep 8, 2026before the open | – | – | -$0.47 | Release |
| Q2 FY2026ended Apr 30, 2026 | Jun 15, 2026before the open | – | – | -$0.43 | Release |
| Q1 FY2026ended Jan 31, 2026 | Mar 9, 2026before the open | – | – | $0.44 | Release |
| Q4 FY2025ended Oct 31, 2025 | Dec 22, 2025during market hours | – | – | – | Release |
| Q3 FY2025ended Jul 31, 2025 | Sep 11, 2025during market hours | – | – | $0.57 | Release |
| Q2 FY2025ended Apr 30, 2025 | Jun 12, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Jan 31, 2025 | Mar 10, 2025during market hours | – | – | -$0.48 | Release |
| Q4 FY2024ended Oct 31, 2024 | Dec 19, 2024during market hours | – | – | – | Release |
| Q3 FY2024ended Jul 31, 2024 | Sep 10, 2024during market hours | – | – | $0.32 | Release |
| Q2 FY2024ended Apr 30, 2024 | Jun 14, 2024before the open | – | – | $0.38 | Release |
| Q1 FY2024ended Jan 31, 2024 | Mar 11, 2024during market hours | – | – | $0.46 | Release |
| Q4 FY2023ended Oct 31, 2023 | Jan 29, 2024before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
enGene Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When enGene Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases enGene Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- Update
- Update
- Results
- Update
- Update
- Update
- Results
- Update
- Results
- Update
See a number that looks wrong?